SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Madrigal Pharmaceuticals
MDGL 418.90-2.0%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tuck6/20/2019 11:29:36 AM
  Read Replies (1) of 138
 
A competitor with a singular focus on NASH via activation of most - but not all - FGF21 receptor sub-types, is in phase two with its compound. Akero Therapeutics (AKRO) is going public shortly. They claim theirs is the only investigational compound that targets both fibrotic and metabolic pathways. One issue is the weekly sub-q dosing.

AKR-001

Not to be confused with NGM, which is targeting FGF19.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News